Lee, Cheryl T.
Mohamed, Nihal E.
Pisipati, Sailaja
Shah, Qainat N.
Agarwal, Piyush K.
Downs, Tracy M.
Droller, Michael
Gilbert, Scott M.
Goltz, Heather H.
Hall, Simon J.
Hendawi, Mohamed
Hoffman-Censits, Jean
O’Donnell, Michael
Kaag, Matthew
Karsh, Lawrence I.
Kassouf, Wassim
Quale, Diane Z.
Sagalowsky, Arthur
Steinberg, Gary D.
Latini, David M.
Funding for this research was provided by:
Bladder Cancer Advocacy Network (Small grant of $50000 without number dates Sept 2010 - June 2014)
Article History
Received: 28 October 2019
Accepted: 13 July 2020
First Online: 24 July 2020
Ethics approval and consent to participate
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Institutional Review Board (IRB) of the University of Michigan (the lead institution) and the participating institutions (Study HUM00056082). Informed verbal consent was obtained from all individual participants included in the study.
: Not applicable.
: Authors SP, QNS, PKA, TMD, MD, SMG, HHG, MH, MOD, MK, WK, DZQ, AS, GDS, DML declare that they have no conflicts of interest.CTL received a research grant from MelRite and is a consultant with Merck. She has no conflicts related to the content of this manuscript.NEM received research grants from The National Institute of Health and The American Cancer Society. She received an honorarium for participating in the Incyte Bladder Cancer Advisory Board.SH received a research grant from National Cancer Institute.JHC received research funding from Genetech/Roche and is a consultant with Astra-Zeneca, Genetech/Roche, Foundation Medicine. She has no conflicts related to the content of this manuscript.LIK received research funding from Astellas, Allergan, AstraZeneca, Augmenix, Bayer, BioXcel, CU Optics, CUSP Lancelot, Dendreon, Exact Sciences, Ferring, FKD, Genetech/Roche, GenomeDx, Genomic Health, Janssen, Merck, Myovant, Nucleix, Pfizer, Pharmtech/Veru, Precision Biopsy, Precision Med, Siemens, Spectrum, Urogen, Vaxiion. He is a Consultant / Advisory for 3D Biopsy, Abbvie, Astellas, Astra-Zeneca, Augmenix, Bayer, Dendreon, Ferring, Janssen, Pfizer, Precision Biopsy, Spectrum, Vaxiion<b>.</b> He is a speaker for Amgen, Astellas, Bayer, Janssen, Pfizer and is the owner of Swan Valley Medical. He has no conflicts related to the content of this manuscript.